SURVYR

TNGX

Tango Therapeutics, Inc.
$22.89
+$0.69 (3.13%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-14%+75%+164%+253%+343%Oct 2025Oct 2026Apr 202652w high $34.3952w low $6.69
TNGXSPY
Wall St. Highest PT $69.00 (+201.4%) Wall St. Avg PT $44.88 (+96.1%)
$8$23$39$55$71POC $23Hi $69Avg $45
Underwater Drawdown %Max DD -33.9%Current -30.4%
0.0%-33.9%
Relative Strength vs SPY+181.1% vs SPYOutperforming
+360%0%-360%
1W
−$2.36 (9.35%)
1M
−$2.03 (8.15%)
3M
−$3.76 (14.11%)
6M
−$2.25 (8.95%)
YTD
+$14.03 (158.35%)
1Y
+$15.12 (194.59%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.23
1 = Strong Buy · 5 = Sell
Strong Buy1185%
Buy18%
Hold18%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 22, 2026
Analyst price targets
Current price$22.89
Average target$44.88
+$21.99 (+96.1%) upsideaverage target vs current price
CurrentAverageMedian
Low$24.00
Median$40.77
High$69.00
12-month Wall Street target range · as of Oct 22, 2026
Recent analyst rating changes · 8
Initiated
2026-10-16 · William Blair started covering TNGX at Outperform
Reiterated
2026-08-18 · HC Wainwright & Co. reiterated Buy on TNGX
Reiterated
2026-08-12 · Guggenheim reiterated Buy on TNGX
Reiterated
2026-07-17 · Mizuho reiterated Outperform on TNGX
Initiated
2026-07-15 · JP Morgan started covering TNGX at Overweight
Reiterated
2026-06-29 · Canaccord Genuity reiterated Buy on TNGX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$4.5B
P/E (next 12 months, estimated)-15.9
52-week range$6.69 – $34.39
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$44.88 (+96%)

What they do

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TNGX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TNGX earningsNext report in 7 days
Next report
Wed Nov 4, 2026Before the open
EPS consensus-$0.35 range -$0.42–-$0.30
Revenue consensus$0 12 analysts
Last 4 quarters · EPS vs estimate
Aug 11, 2026-$0.37est -$0.32−14.2%Below estimates
May 13, 2026-$0.32est -$0.31−1.7%Below estimates
Mar 5, 2026-$0.29est -$0.33+11.8%Above estimates
Nov 4, 2025$0.13est -$0.07+287.4%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:15:37 ET
24-1125-0225-0525-0825-1126-0326-0526-08-0.370.13
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0-100.0%
2026-03-31$0–
2025-12-31$0–
2025-09-30$53.8M–
2025-06-30$3.2M–

News & catalysts

More news
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Benzinga · Oct 23
Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
TIKR · Oct 23
Tango Therapeutics stock falls despite positive cancer trial data
Investing.com · Oct 23
Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial
MT Newswires · Oct 23
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Investor's Business Daily · Oct 23
Rating changes
Initiated
2026-10-16 · William Blair started covering TNGX at Outperform
Reiterated
2026-08-18 · HC Wainwright & Co. reiterated Buy on TNGX
Reiterated
2026-08-12 · Guggenheim reiterated Buy on TNGX
Reiterated
2026-07-17 · Mizuho reiterated Outperform on TNGX
Initiated
2026-07-15 · JP Morgan started covering TNGX at Overweight
Reiterated
2026-06-29 · Canaccord Genuity reiterated Buy on TNGX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Crystal Adam
President, R&D · 2026-10-01
Sell
$15.2K
Crystal Adam
President, R&D · 2026-10-01
Sell
$645.6K
Newcomb Jessica
Principal Accounting Officer · 2026-09-22
Sell
$60.4K
Newcomb Jessica
Principal Accounting Officer · 2026-09-22
Sell
$122.2K
Newcomb Jessica
Principal Accounting Officer · 2026-09-22
Sell
$16.0K
Crystal Adam
President, R&D · 2026-09-01
Sell
$603.9K
Crystal Adam
President, R&D · 2026-08-03
Sell
$594.4K
Crystal Adam
President, R&D · 2026-08-03
Sell
$141.1K

Stats refreshed 2026-10-21 12:15:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026